surpass 4 tirzepatide Effects of versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial π« EASD 2025: Tirzepatide (SURPASS-CVOT)
Pay in 4 interest-free payments of $5.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14























